STACKD summary
Limited human dataMelanotan I, Melanotan II, and bremelanotide: the melanocortin peptide family
Same receptor family, three very different regulatory outcomes, from an approved skin-disease implant to a gray-market tanning shot.
Plain-language summary
These three peptides all trace back to alpha-MSH research at the University of Arizona in the 1980s, and all activate melanocortin receptors, but they've ended up in very different places. Melanotan I is more selective for the skin-pigmentation receptor (MC1R) and, under the name afamelanotide (Scenesse), is FDA-approved as an implant for a rare light-sensitivity disorder. Melanotan II activates receptors more broadly, which is what led researchers to notice it also increases sexual desire, an accidental discovery that led directly to bremelanotide, now FDA-approved as Vyleesi for low sexual desire in premenopausal women. The catch: the "Melanotan 1" and "Melanotan II" sold online for tanning are not the approved products, they're unregulated compounded peptides with none of the manufacturing oversight behind the actual drugs.
What was studied
Two Phase 3 randomized, placebo-controlled trials of afamelanotide in erythropoietic protoporphyria patients; a double-blind, placebo-controlled crossover study of Melanotan II in men with erectile dysfunction using RigiScan monitoring; and the RECONNECT Phase 3 trials of bremelanotide in premenopausal women with hypoactive sexual desire disorder.
Key takeaways
- Two of the three, afamelanotide (Melanotan I's approved form) and bremelanotide, are genuinely FDA-approved drugs with Phase 3 trial data behind them, a rarer regulatory status than most peptides on this site.
- Melanotan II itself was never approved for any use; it's the compound whose sexual-desire side effect in early human trials led directly to bremelanotide's development, giving it a real if indirect place in an approved drug's history.
- The approved products use specific, clinician-administered delivery methods, an implant for afamelanotide, an as-needed autoinjector for bremelanotide, not the self-injected tanning-focused dosing common in gray-market use.
- Nausea, flushing, and headache are consistently reported across the whole family, and case reports outside formal trials describe darkened or new pigmented moles with unsupervised Melanotan use.
Limitations & what we don't know
- The FDA approvals are narrow: afamelanotide for erythropoietic protoporphyria specifically, bremelanotide for HSDD in premenopausal women specifically, neither a general tanning or libido product.
- Products sold online as "Melanotan 1" or "Melanotan 2" for cosmetic tanning are unregulated and have never been evaluated by the FDA for safety, purity, or potency in that use.
- Bremelanotide's clinical trial benefit, while statistically significant, has been described by reviewers as modest in absolute terms.
- Melanotan II has no approved indication of its own; its human data is limited to smaller, earlier-stage erectile-function studies, not the tanning use it's actually sold for.
Sources
Primary citations behind this summary. External links are provided for verification, read them yourself before drawing conclusions.